Aklog described the VA contract as a key milestone, stating Lucid was awarded a contract for EsoGuard under the VA Federal Supply Schedule (FSS) , which centralizes ordering and sets pricing aligned with the company’s established Medicare rate of $1,938 . He said securing the contract without discounting relative to Medicare was an important validation of the company’s clinical evidence.In the Q&A, management said the sequential increase in volume was not attributable to VA testing, which is still in the ea ...

Lucid Diagnostics (NasdaqCM:LUCD) Q4 2025 Earnings call March 26, 2026 08:30 AM ET Company ParticipantsDennis McGrath - CFOJeremy Pearlman - Senior Research AssociateLishan Aklog - Chairman and CEOMatt Riley - VP of Investor RelationsConference Call ParticipantsKyle Mikson - Managing Director and Senior Research AnalystMark Massaro - Managing Director and Life Science and Diagnostic Tools AnalystMike Matson - Senior AnalystOperatorGood morning, and welcome to the Lucid Diagnostics fourth quarter 2025 busine ...

Financial Data and Key Metrics Changes - Milestone Pharmaceuticals reported $1.5 million in revenue for Q4 2025, with no revenue comparables in 2024, reflecting earnings under a licensing collaboration agreement following FDA approval of CARDAMYST [19] - R&D expenses for Q4 2025 were $5.5 million, up from $3.9 million in Q4 2024, with full-year R&D expenses at $18.1 million compared to $14.4 million in 2024 [19] - G&A expenses increased to $5.1 million in Q4 2025 from $4.0 million in the prior quarter, with full-year G&A expenses at $17.3 million compared to $16.7 million in 2024 [20] - Commercial expenses rose significantly to $8.2 million in Q4 2025 from $4.4 million in Q4 2024, with full-year commercial expenses at $28.3 million compared to $11 million in 2024 [20] - The net loss for Q4 2025 was $17.4 million or $0.16 per share, compared to a net loss of $12.4 million or $0.19 per share in Q4 2024 [20] - Full-year net loss was $63.1 million or $0.75 per share, compared to $41.5 million or $0.67 per share in 2024 [21] Business Line Data and Key Metrics Changes - The launch of CARDAMYST is seen as a pivotal moment for the company, targeting over 2 million patients with PSVT, marking the first new therapeutic option in 30 years [4][5] - The commercial strategy focuses on driving new patient starts and achieving commercial coverage, with a sales force of approximately 60 representatives targeting around 10,000 providers [10] Market Data and Key Metrics Changes - The company has filed a marketing authorization application for CARDAMYST in Europe, with expectations for a decision in the first half of 2027 [7] - The company is actively engaging with payers to demonstrate the value proposition of CARDAMYST, aiming to reduce emergency department visits and hospital utilization [11] Company Strategy and Development Direction - The FDA approval of CARDAMYST is viewed as a foundation for value creation, with a focus on building a strong commercial franchise [5] - The company aims to leverage comprehensive clinical data to seek marketing approvals in other regions, enhancing the credibility of CARDAMYST [6] - The strategy includes ensuring a positive initial experience for patients and prescribers, with a focus on accessibility and affordability [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early feedback from prescribers and the initial launch of CARDAMYST, indicating strong demand generation [12][18] - The company anticipates prescription volume to increase and commercial coverage to expand over time, with more meaningful progress expected in the latter half of the year [18] Other Important Information - The company reported a pro forma estimated cash figure of $200 million, supporting the successful launch of CARDAMYST and providing an operating runway into late 2027 [7][22] - The leadership team has been enhanced with the addition of David Sandoval as General Counsel and Chief Compliance Officer [8] Q&A Session Summary Question: Feedback on CARDAMYST launch and coverage denial reasons - Management noted a broad mix of prescribers adopting CARDAMYST, including cardiologists and advanced practice providers, with coverage denials primarily due to paperwork requirements for patient eligibility [26][28] Question: Reimbursement timelines and patient access - Management indicated that scripts are being filled within days to weeks once the system is engaged, with ongoing efforts to support patients in accessing the drug during the delay period [32][35] Question: Current prescribing trends and patient mix - Management reported that CARDAMYST is being prescribed to a diverse patient group, including those awaiting ablation and those with existing medications, but emphasized that it is too early to identify specific trends [43][44] Question: Contracting strategy and formulary positioning - The company aims for broad access with reasonable coverage terms, targeting commercial plans first, with Medicare coverage expected to follow in 2027 [50][57]

Washington Mayor Muriel Bowser declares an emergency over the massive sewage spill in the Potomac River and asks Trump for a disaster declaration and reimbursement for costs incurred by the District of Columbia https://t.co/Zbqk8RyhpQ ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][11] - Full year gross margin was 82.1%, down from 85.8% in 2024, reflecting inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] Business Line Data and Key Metrics Changes - Approximately 90% of revenue comes from about 200 burn and trauma centers, with a focus on increasing adoption and utilization of products like RECELL, Cohealyx, and PermeaDerm [6][7] - The Cohealyx I post-market study is fully enrolled, and the PermeaDerm I study is nearing full enrollment, with data expected later in 2026 [8] Market Data and Key Metrics Changes - Six of the seven Medicare administrative contractors have published payment rates for RECELL procedures, which is expected to restore confidence among clinicians [6] - The company is taking a disciplined distributor-led approach in select international markets, focusing on establishing operational readiness [9] Company Strategy and Development Direction - The company aims to drive disciplined execution, refine commercial focus, and position for growth in 2026, with a strategy centered around an integrated platform of products [4][10] - The company expects full year revenue of $80 million to $85 million in 2026, representing growth of approximately 12% to 19% over 2025 [10] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of predictable reimbursement for products and the need for increased adoption and utilization by clinicians [6][18] - The company is focused on maintaining disciplined control of operating costs and supporting revenue growth with a stable cost structure [17] Other Important Information - The company refinanced its debt through a new credit facility, which provides more flexibility and reduces covenant risk [15][16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining from $10.1 million in Q2 to $5.1 million in Q4 [15] Q&A Session Summary Question: Guidance on revenue covenants and growth pace - Management clarified that the $15.4 million covenant is not a guidance figure and that they expect growth to continue from Q4 into Q1 and throughout the year [20][21] Question: Reimbursement dynamics affecting 2025 - Management confirmed engagement with all seven MACs and expressed optimism about the seventh MAC publishing payment rates soon [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management discussed the process of working with champions in accounts to facilitate the adoption of Cohealyx and PermeaDerm, noting early positive experiences [37][38] Question: Drivers of growth for 2026 guidance - Management indicated that growth will come from increased utilization within existing accounts and contributions from Cohealyx and PermeaDerm [49]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $17.6 million and full-year revenue of approximately $71.6 million, representing about 11% growth over 2024 [5][12] - Full year gross margin was 82.1%, down from 85.8% in 2024, reflecting inventory reserves and product mix changes [12] - Fourth quarter gross margin was 81.2%, compared to 87.6% for the same period last year [13] - Total operating expenses in the fourth quarter were $24.7 million, down 5% year-over-year, primarily due to lower sales and marketing expenses [14] Business Line Data and Key Metrics Changes - The company focused on increasing adoption and utilization of its products, with approximately 90% of revenue coming from about 200 burn and trauma centers [6][8] - The Cohealyx I post-market study is fully enrolled, and the PermeaDerm I study is nearing full enrollment, with data expected later in 2026 [9] Market Data and Key Metrics Changes - Six of the seven Medicare administrative contractors have published payment rates for RECELL procedures, which has begun to restore confidence for clinicians [6] - The company is taking a disciplined distributor-led approach to build its footprint in select international markets [10] Company Strategy and Development Direction - The company aims to drive disciplined execution, refine commercial focus, and position itself for growth in 2026 [4] - The strategy is built around a single integrated platform of RECELL, Cohealyx, and PermeaDerm, used repeatedly by the same clinicians [8] - The company expects full year revenue of $80 million-$85 million in 2026, representing growth of approximately 12%-19% over 2025 [11] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of predictable reimbursement for products and clinicians to drive routine use of RECELL [6] - The company is focused on establishing the right operating cadence and executing fundamentals well to ensure consistent progress [8] - Management expressed confidence in the normalization of RECELL utilization and the expansion of portfolio use within core accounts [11] Other Important Information - The company refinanced its debt through a new credit facility, which provides more flexibility and reduces covenant risk [15][16] - The fourth quarter marked the third consecutive quarter of improvement in net cash use, declining to $5.1 million [15] Q&A Session Summary Question: Guidance on revenue growth pace - Management clarified that the $15.4 million revenue covenant is not a guidance figure and that they expect progressive growth from Q4 to Q1 and throughout the year [22][26] Question: Reimbursement dynamics affecting 2025 - Management confirmed that they are engaged with all seven MACs and are hopeful for the seventh MAC to publish payment rates soon [30][31] Question: Customer experience with Cohealyx and PermeaDerm - Management indicated that champions in accounts are helping to push Cohealyx and PermeaDerm through the VAC process, with early signs of uptake [37][38] Question: Drivers of growth for 2026 guidance - Management expects growth from all three product lines, primarily driven by increased utilization within existing accounts [48]

Core Insights - Inspire Medical Systems announced the appointment of Matt Osberg as Executive Vice President and Chief Financial Officer, effective January 19, 2026 [3][4] - The company provided preliminary, unaudited revenue results for the fourth quarter and full year 2025, with fourth quarter revenue expected to be between $268.9 million and $269.1 million, representing a 12% increase year-over-year [6] - For the full year 2025, revenue is anticipated to be in the range of $911.8 million to $912.0 million, marking a 14% increase compared to 2024 [6] - Inspire's revenue guidance for 2026 is projected to be between $1,003 million and $1,013 million, indicating a growth of 10% to 11% over 2025 [2] Financial Performance - The fourth quarter revenue for 2025 is expected to show a strong performance, contributing to the overall positive momentum for the company [2] - The company experienced significant growth in the second half of 2025, particularly following the launch of the Inspire V system [2] - Inspire's revenue growth outlook for 2026 does not currently factor in potential increases from reimbursement developments [2] Leadership Changes - Matt Osberg brings over 20 years of financial leadership experience to Inspire, having previously served as CFO at Apogee Enterprises and Helen of Troy [3][4] - The appointment of Osberg is seen as a strategic move to guide the company through its next growth phase [4] Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for obstructive sleep apnea [8] - The company's Inspire therapy is recognized as the first FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [8]

Core Insights - Inspire Medical Systems (INSP) is positioned for growth due to a significant product transition, with management highlighting clinical momentum, improved reimbursement visibility, and disciplined cost control, despite facing near-term challenges related to inventory conversion and competition [2][12][14] Company Overview - Inspire Medical focuses on innovative, minimally-invasive solutions for obstructive sleep apnea, with a market capitalization of $2.81 billion. The company anticipates a 39.1% earnings decline for Q4 2025, but expects earnings growth to resume in 2026 [4] Financial Performance - INSP shares have decreased by 12.5% over the past six months, while the industry has declined by 16.3%, and the S&P 500 has increased by 16.3% during the same period [3] - The company has consistently surpassed earnings estimates in the last four quarters, achieving an average surprise of 164.19% [6] Positive Factors Driving Prospects - The launch of Inspire V is a key growth driver, with strong clinical data supporting its adoption, including reduced surgical times and high nightly usage. Adoption has accelerated, reaching over 75% of implanting centers [7] - Reimbursement trends are favorable, with an 11% increase in the physician fee schedule for CPT 64568 effective January 2026, enhancing the economic viability for hospitals [8][9] - The adoption of GLP-1 therapies is increasing patient flow into sleep clinics, which could lead to more referrals for Inspire Medical as noncompliance with CPAP emerges [10] Operational Discipline - The company has demonstrated operational discipline, achieving earnings upside through gross margin expansion and cost control, despite increased marketing expenses [11] Key Challenges - The transition from Inspire IV to Inspire V presents complexities, with some centers continuing to use Inspire IV for economic reasons, which complicates inventory forecasting [12] - Uncertainty exists around GLP-1 trialing, which may delay surgical interventions and impact short-term volume growth [13] - Elevated operating expenses and competition pose challenges to maintaining margin expansion, as operating expenses growth outpaces revenue growth [14] Estimate Trend - The Zacks Consensus Estimate for earnings in 2025 is $1.71 per share, with Q4 2025 revenue estimated at $262.9 million and a loss per share of 70 cents [15]

Summary of The Pennant Group FY Conference Call Company Overview - **Company**: The Pennant Group (NasdaqGS:PNTG) - **Industry**: Home health and hospice services, senior living facilities Key Points and Arguments 1. Growth and Acquisitions - The Pennant Group had a productive year in 2025, starting with the second tranche of the Signature acquisition and culminating in the purchase of a large portfolio from UnitedHealth and Amedisys [25][26] - The company emphasizes investment in leadership, which has led to organic growth in operations, surpassing previous performance levels [27][28] 2. Integration Process - The integration of new acquisitions involves a structured approach focusing on leadership readiness, operational health, and the opportunity presented by the acquisition [31][32] - A typical optimization process post-acquisition spans about nine quarters, involving technology integration and rebranding efforts [33][34] 3. Financial Management - The company expects G&A costs to normalize from approximately 6.7% to 6.5% by the end of 2026, despite initial increases due to acquisitions [36][37] - Current leverage is around two times net debt to adjusted EBITDA, with a comfortable range of two to two and a half times for future acquisitions [39][40] 4. Referral Dynamics and Partnerships - The partnership with Ensign has provided operational benefits, including shared expertise and clinical collaboration, although referrals from Ensign's skilled nursing operations remain low [46][47] - The company is exploring joint venture opportunities with health systems to enhance care delivery and improve clinical outcomes [66][67] 5. Reimbursement and Quality Measures - The Pennant Group has achieved a 4.1 CMS Star Rating, which has helped reduce the differential between Medicare Advantage (MA) rates and fee-for-service rates to 20-25% [58][59] - The company is focused on driving down costs while maintaining quality, which is crucial for negotiations with payers [61][62] 6. Hospice Operations - The company sees potential for growth in hospice length of stay, currently just under 100 days, with a target to improve without exceeding caps [76][77] - The hospice segment is expected to grow in the mid to high single digits, with a focus on maintaining quality care [78][79] 7. Senior Living Performance - The senior living segment has seen high occupancy rates and successful rate increases, attributed to capital investments and improved service offerings [88][89] - The company aims to increase the proportion of healthcare services provided, currently at 20-25%, with a long-term goal of 25-33% [91][92] 8. Labor and Staffing - The company has made significant improvements in caregiver onboarding and retention, leading to decreased turnover and enhanced employee experience [94] - Current staffing levels are sufficient to support increased occupancy, with ongoing efforts to scale as demand grows [94] 9. Future Outlook - The Pennant Group is targeting a 15% margin in senior living, with expectations that increased occupancy and operational efficiencies will contribute to this goal [96][97] Additional Important Insights - The company is actively involved in discussions with CMS regarding reimbursement methodologies, emphasizing the importance of home health services in the continuum of care [71][72] - The focus on leadership development and creating opportunities for local leaders is a core part of the company's strategy, differentiating it in a fragmented market [50][54]

Summary of Tempus AI Conference Call Company Overview - **Company**: Tempus AI - **Industry**: Life Sciences and Diagnostics Key Points AI Integration in Diagnostics and Biopharma - Tempus AI leverages AI across its operations, focusing on enhancing patient care through data and technology [4][5][6] - The company has developed platforms like Hub and Lens to facilitate interaction with diagnostic tests and build patient cohorts, respectively [4][5] - A partnership with AstraZeneca and Pathos aims to create a foundation model to extract insights from large datasets [6] Financial Performance - The third quarter reported a **28% organic growth**, with specific segments showing: - **Genomics**: High 20s growth - **Ambry**: 33% growth - **Data Licensing**: 37% growth [10][12] - Adjusted EBITDA turned positive, marking a significant milestone for the company [13] Oncology and Hereditary Testing - Oncology volumes grew by **27%**, while Ambry benefited from market disruptions in hereditary screening [12][42] - The hereditary testing market is expected to moderate as share gains stabilize [12] Data Licensing and Contracts - Total remaining contract value exceeded **$1 billion**, with a net revenue retention rate of **140%** [48] - New contracts included a **$66 million deal** with a biotech customer and expansions with existing clients [48] - The company anticipates strong engagement from both big pharma and biotech sectors [48] Market Position and Competition - Tempus AI has established connections with over **5,000 institutions**, enhancing its data collection and diagnostic capabilities [19] - The company emphasizes ease of use and connectivity as key differentiators against competitors [20] Reimbursement Trends - Average Selling Prices (ASPs) have increased to approximately **$1,600**, with expectations for **40%** of xT volumes to transition to ADLT pricing by year-end [22][23] - The company aims for **85%** of xT volumes to shift to ADLT pricing by the end of 2026 [23] Clinical Trials and CRO Business - The CRO segment has faced headwinds, but the acquisition of a small CRO aims to enhance clinical trial matching capabilities [61] - The company does not prioritize aggressive growth in the CRO sector but sees potential stabilization as funding for CROs improves [61] Investment and Growth Strategy - Tempus AI plans to reinvest about **two-thirds** of incremental gross profit back into the business over the next three years to support growth [64] - The company aims for long-term growth rates of **25-30%**, focusing on sustainable growth rather than maximizing quarterly revenue [58][64] Gross Margins and Future Outlook - Genomics business margins are expected to stabilize around **low 60%**, while data operations may achieve **mid 70%** margins [66] - AI applications, though currently a small revenue source, are anticipated to positively impact margins as they scale [68] Upcoming Developments - Data from a new ultra-high sensitivity assay for MRD is expected in **2026**, with further developments in breast cancer and immuno-oncology to follow in **2027** [38][39] Additional Insights - The company is cautious about the competitive landscape in MRD testing, focusing on leveraging existing data connections and insights to gain market share [34][35] - Tempus AI's strategy emphasizes long-term relationships with clients to ensure sustained growth and value delivery [58][59]